Villepinte (France), June 29, 2020 - 18:00 CET - Guerbet (GBT), a global leader in medical imaging, has launched a new “consumables.guerbet.com” website presenting its Essential and Excellence ranges of consumables for use with injection solutions and tailored for diagnostic imaging professionals.
Essential certified by Guerbet is a range of easy-to-use consumables certified by Guerbet and supplied by manufacturers selected by the company. They are all tested and approved according to Guerbet quality standards and comply with medical devices regulations.
Excellence designed by Guerbet is a range of consumables designed from Guerbet research offering innovative1 safety features and improving the workflow of injection procedures.
“We have segmented our consumables in two clearly identified Essential and Excellence ranges to make it easier for healthcare professionals to reach decisions. All our consumables are compatible with our CT, Cath Lab and MRI injection systems and benefit from our commitment to delivering safe, high-quality solutions crucial for improving patient prognosis and quality of life,” says Valérie Brissart, Global Marketing Director of CT and Cath Lab Imaging Solutions at Guerbet.
Both ranges of consumables offer syringes and kits, patient lines, day-sets, tubing and accessories for each of the Guerbet power injectors: OptiVantage® Multi-use, OptiVantage® Single-use, Illumena® Néo, FlowSens®, OptiStar® Elite, OptiOne®.
Not all products available in all countries. Consult with your local representative for more information. For complete product information, please refer to the legal mentions, available at consumables.guerbet.com.
1Vermeulen C, Noury B & Al. - Microbial Safety Assessment of a Double Check-Valve Patient Line in a Multi-use Contrast Delivery System Radiol Technol. 2015 Nov-Dec;87(2):139-49
Guerbet is a leader in medical imaging worldwide, offering a wide range of pharmaceutical products, medical devices, digital and AI solutions for diagnostic and interventional imaging, to improve the diagnosis and treatment of patients. A pioneer since more than 90 years in the field of contrast media with over 2,800 people globally, Guerbet is continuously innovating with 9% of revenue dedicated to Research & Development and four centers in France, Israel and the United States. Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps) and generated €817 million in revenue in 2019. For more information about Guerbet, please visit www.guerbet.com.
+33 (0) 6 64 18 99 59 / firstname.lastname@example.org